Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy after surgery and for advanced metastatic disease. By inhibiting estrogen synthesis, letrozole reduces the hormonal stimulus that drives tumor proliferation.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozol Sandoz, an aromatase inhibitor, is used in the management of hormone‑dependent breast cancer. - Hormone receptor‑positive early breast cancer: reduces risk of recurrence when given as adjuvant therapy after surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression and prolongs survival. - Neoadjuvant setting: decreases tumor size before surgery in eligible patients.

Letrozol Sandoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate intensity. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fractures: increased risk of osteoporosis‑related breaks. - Deep vein thrombosis or pulmonary embolism: swelling, pain, shortness of breath. - Allergic reactions: rash, itching, angioedema. - Cardiovascular events: hypertension, myocardial infarction.

When prescribing Letrozol Sandoz, clinicians should observe several precautionary measures to ensure patient safety. - Assess bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Monitor liver function: perform periodic liver enzyme tests during therapy. - Evaluate cardiovascular risk: watch for signs of thromboembolic events, especially in high‑risk patients. - Avoid use in pregnancy: contraindicated due to teratogenic risk; ensure effective contraception in women of child‑bearing potential. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Letrozol Sandoz can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent estrogen therapy: antagonizes letrozole’s estrogen‑lowering effect. - Strong CYP2C19 inhibitors (e.g., fluconazole, voriconazole): raise plasma concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower letrozole levels, reducing effectiveness. - Tamoxifen: may compete for metabolic pathways, altering both drugs’ activity. - Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.